Kutatási jelek – Signal Engine
- Cervical cancer could be eliminated within a century — Cervical cancer
- European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia — Chronic myeloid leukemia
- Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Trial — Nasopharyngeal carcinoma
- Head and neck squamous cell carcinoma — Head and neck squamous cell carcinoma
- Waldenström Macroglobulinemia: Clinical Presentation, Diagnosis, and Management — Waldenstrom macroglobulinemia
- Convergent and Divergent Signaling Pathways in Cancer: A Dual‑Axis Model for Adaptive Precision Oncology — NSCLC
- Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with venetoclax: a multicenter retrospective analysis — Waldenstrom macroglobulinemia
- Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma — Nasopharyngeal carcinoma
- Projected time to elimination of cervical cancer in the USA: a comparative modelling study — Cervical cancer
- Nivolumab Plus Ipilimumab for Treatment‑Naïve Metastatic Uveal Melanoma: An Open‑Label, Multicenter, Phase II Trial — Melanoma
- Adrenocortical Carcinoma — Adrenocortical carcinoma
- Cervical cancer: Epidemiology, risk factors and screening — Cervical cancer
- Advances in targeted therapy for esophageal cancer — Esophageal cancer
- Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions — Melanoma
- Effectiveness of Integrated Palliative and Oncology Care for Patients with Acute Myeloid Leukemia — Lymphoma
- Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer — Colorectal cancer
- Lurbinectedin as second‑line treatment for patients with small‑cell lung cancer: a single‑arm, open‑label, phase 2 basket trial — SCLC
- Precision Medicine CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer — Breast cancer
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. — NSCLC
- Pembrolizumab for Early Triple‑Negative Breast Cancer — Breast cancer